* CytoMed Inc., of Cambridge, Mass., entered a drug discovery collaboration with UCB Pharma, of Brussels, Belgium, for inflammatory diseases. Financial terms were not disclosed. UCB Pharma is a division UCB Group, in Brussels.

* Mycogen Corp., of San Diego, said a California superior court jury awarded the company $174.9 million in damages in its long-running breach of contract litigation against Monsanto Co., of St. Louis. The dispute involves technology licensing options granted by Monsanto in 1989 to Lubrizol Genetics, of Wickcliff, Ohio, which Mycogen acquired in 1992. Monsanto said it will ask the trial judge to set aside the damage award.

* Myelos Neurosciences Corp., of San Diego, said a Phase I trial of its lead compound, Prosaptide TX14(A), demonstrated the drug was safe and well tolerated. The compound is targeted for treatment of pain and peripheral neuropathies. The company said the peptide drug has shown an ability "to induce neuronal regeneration, prevent neuronal death, alleviate peripheral neuropathy and relieve neuropathic pain."

* PathoGenesis Corp., of Seattle, said it filed a new drug submission in Canada for TOBI, the company's inhaled form of the antibiotic tobramycin, to treat Pseudomonas aeruginosa infections in cystic fibrosis patients. PathoGenesis said the Canadian regulatory authorities granted the drug priority review.

* Progenitor Inc., of Menlo Park, Calif., entered a technology sharing collaboration with Cambridge Antibody Technology Group plc (CAT), of Royston, U.K. Progenitor will supply CAT with gene targets for therapeutic antibodies and CAT will provide Progenitor with antibody reagents for use in understanding its gene functions. CAT and Progenitor also initiated a antibody-based drug discovery program targeting the latter's discovery of the leptin receptor gene, which is linked to obesity and diabetes.

No Comments